Health utilities associated with hemoglobin levels and blood loss in postmenopausal women: the Women's Health Initiative.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Value in Health

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jval.2010.11.008PMID 21669380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer

  2012cited by this paper
• Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis

  2009cited by this paper
• The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model

  2008cited by this paper
• Cost-effectiveness analysis of treatment with epoietin-α for patients with anaemia due to renal failure: The case of Sweden

  2008cited by this paper
• Health state utility scores for cancer-related anemia through societal and patient valuations.

  2008cited by this paper
• Association of anemia and physical disability among patients with rheumatoid arthritis.

  2007cited by this paper
• Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.

  2006cited by this paper
• Race/Ethnicity, Socioeconomic Status, and Lifetime Morbidity Burden in the Women's Health Initiative: A Cross-Sectional Analysis

  2006cited by this paper
• Cost‐effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

  2006cited by this paper
• Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.

  2005cited by this paper
• Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D

  2005cited by this paper
• Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.

  2005cited by this paper
• Economic burden of patients with anemia in selected diseases.

  2005cited by this paper
• Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.

  2005cited by this paper
• The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures.

  2003cited by this paper
• The estimation of a preference-based measure of health from the SF-36.

  2002cited by this paper
• Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

  2001cited by this paper
• Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview.

  2001cited by this paper
• Factors influencing quality of life in cancer patients: anemia and fatigue.

  1998cited by this paper
• Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.

  1998cited by this paper
• Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

  1998cited by this paper
• The Women's Health Initiative Clinical Trial and Observational Study: history and overview.

  1994cited by this paper
• Development of a Brief Screening Instrument for Detecting Depressive Disorders

  1988cited by this paper

• Canadian Association of Gastroenterology Clinical Practice Guideline for the Endoscopic Management of Nonvariceal Nonpeptic Ulcer Upper Gastrointestinal Bleeding.

  2025cites this paper
• Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system

  2023cites this paper
• Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review

  2020cites this paper
• Title Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty ?

  2019cites this paper
• Does Prophylactic Administration of Edoxaban Increase D-Dimer Levels after Total Hip Arthroplasty?

  2019cites this paper
• The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.

  2017cites this paper
• The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.

  2016influential citation
• Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer [ID794]: Multiple Technology Appraisal (MTA)

  2015cites this paper
• Healthcare resource utilization and economic impact of a ≥2 g/dL decrease in hemoglobin in osteoarthritis patients

  2013cites this paper